



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

SEP 12 2002

16464

TECH CENTER 1600/2900

PATENT

Atty. Docket No. DX01135

CN 028008

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

on September 5, 2002.

By: Lois Miller

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Megan K. LEVINGS, et al.

Serial No.: 09/929,863

Filed: August 14, 2001

For: REGULATORY T CELLS;
METHODS

Examiner: Janet L. ANDRES

Art Unit: 1646

**INFORMATION DISCLOSURE
STATEMENT**

Palo Alto, California 94304

Sept 4, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The materials as listed in the attached modified PTO 1449 form are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98.


Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

09-1178902 R09211 00000000 041124 04-26-02
01 FC:126 180,00 10

Applicants request that the Examiner fully consider the art cited in the attached modified PTO 1449 form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Since this Information Disclosure Statement is being filed after receiving the first Office action, a fee of \$180.00 is required for filing this document. The Commissioner is hereby authorized to charge this fee to DNAX Research Institute's Deposit Account No. 04-1239.

Respectfully submitted,

By: 

Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

Enclosures: Modified PTO 1449 form (2 pages)
References AA-AR (18 refs.)



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

SEP 12 2002

Sheet 1 of 2

TECH CENTER 1600
DX01135

SERIAL NO.:
09/929,863

FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
FOR PATENT

(Use several sheets if necessary)

TECH CENTER 1600
DX01135

APPLICANT:
Megan K. LEVINGS, et al.

FILING DATE:
August 14, 2001

GROUP:
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA	Rosa Bacchetta, et al., J Exp Med., 179(2):493-502, February 1, 1994. "High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells"
AB	Frank Bridoux, et al., J Exp Med., 185(10):1769-75, May 19, 1997. "Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines"
AC	Jan Buer, et al., J Exp Med., 187(2):177-183, January 19, 1998. "Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells energized in vivo"
AD	Marina Cella, et al., Nature Medicine, 5(8):919-23, August 1999. "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon"
AE	Nitya G. Chakraborty, et al., J Immunol., 162(9):5576-83, May 1, 1999. "Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines"
AF	Herve Groux, et al., J Immunol., 160(7):3188-93, April 1, 1999. "Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells"
AG	Ui Yen Khoo, et al., J Immunol., 158(8):3626-34, April 15, 1999. "CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens"
AH	Philippa Marrack, et al., J Exp Med., 189(3):521-30, February 1, 1999. Type I interferons keep activated T cells alive.
AI	Sampsu Matikainen, et al. Blood, 93(6):1980-91, March 15, 1999. "Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells"
AJ	Bradford L. McRae, et al., J Immunol. 160(9):4298-304, May 1, 1998. "Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development"
AK	Carla Miller, et al., J Exp Med., 190(1):53-64, July 5, 1999. "Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

Sheet 2 of 2

FORM PTO-1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: DX01135	SERIAL NO.: 09/929,863
INFORMATION DISCLOSURE STATEMENT FOR PATENT					APPLICANT: Megan K. LEVINGS, et al.	
(Use several sheets if necessary)					FILING DATE: August 14, 2001	GROUP: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	AL	Fiona Powrie, et al., J Exp Med., 183(6):2669-74, June 1, 1996. "A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells"				
	AM	Lars Rogge & Francesco Sinigaglia, Chem Immunol., 68:38-53, 1997. "Early events controlling T-helper cell differentiation: the role of the IL-12 receptor"				
	AN	Lars Rogge, et al., J Immunol., 161(12):6567-74, December 15, 1998. "The role of Stat4 in species-specific regulation of Th cell development by type I IFNs"				
	AO	Robert A. Seder, et al., J Immunol., 160(12):5719-28, June 15, 1998. "Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production"				
	AP	Frederick P. Siegal, et al., Science, 284(5421):1835-7, June 11, 1999. "The nature of the principal type 1 interferon-producing cells in human blood"				
	AQ	Thierry Sornasse, et al., J Exp Med., 184(2):473-83, August 1, 1996. "Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level"				
	AR	Anette Sundstedt, et al., J Immunol., 158(1):180-6, January 1, 1997. "Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo"				
EXAMINER			DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>						